380 results on '"Lalive, Patrice"'
Search Results
2. High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study
3. Obstructive sleep apnea: a major risk factor for COVID-19 encephalopathy?
4. Motor-neuron-disease-like phenotype associated with IgLON5 disease
5. Cerebrovascular Complications and Vessel Wall Imaging in COVID-19 Encephalopathy—A Pilot Study
6. CD4+c-Met+Itgα4+ T cell subset promotes murine neuroinflammation
7. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
8. C-reactive protein and white matter microstructural changes in COVID-19 patients with encephalopathy
9. c-Met enforces proinflammatory and migratory features of human activated CD4+ T cells
10. IL-8 as a potential biomarker in Guillain-Barre Syndrome
11. Teaching NeuroImage: Pontine Owl-Eyes Lesions in a Case of Neuroborreliosis
12. Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
13. Multicentric evaluation of a specific intrathecal anti-Treponema pallidum IgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case-control study.
14. Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP
15. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis
16. Serum neurofilament light chains in MS: Association with the Timed Up and Go
17. c-Met is expressed by highly autoreactive encephalitogenic CD8+ cells
18. c-Met + Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models.
19. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.
20. COVID-19–related encephalopathy responsive to high-dose glucocorticoids
21. Risk of MS relapse after yellow fever vaccination: A self-controlled case series
22. Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
23. Personality as a Predictor of Disability in Multiple Sclerosis.
24. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis
25. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
26. Markers of limbic system damage following SARS-CoV-2 infection.
27. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen
28. Stride time variability as a marker for higher level of gait control in multiple sclerosis: its association with fear of falling
29. Gait variability in multiple sclerosis: a better falls predictor than EDSS in patients with low disability
30. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland--A Structured Commentary, Update 2022.
31. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
32. Brain functional connectivity alterations associated with neuropsychological performance 6–9 months following SARS‐CoV‐2 infection.
33. Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes
34. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25⁺Foxp3⁺ regulatory T cells
35. Glatiramer Acetate Increases IL-1 Receptor Antagonist but Decreases T Cell-Induced IL-1β in Human Monocytes and Multiple Sclerosis
36. Antibody response in MOG35–55 induced EAE
37. Antibodies to Native Myelin Oligodendrocyte Glycoprotein Are Serologic Markers of Early Inflammation in Multiple Sclerosis
38. Paraneoplastic Autoimmune Limbic Encephalitis Associated with an Atypical Carcinoid Tumor of the Lung: A Case Report.
39. The Two-Way Route between Delirium Disorder and Dementia: Insights from COVID-19.
40. Transient gadolinium leakage in natalizumab-treated multiple sclerosis
41. Minimal supportive treatment in natalizumab-related PML in a MS patient
42. Anomalous brain dominance and the immune system: Do left-handers have specific immunological patterns?
43. 18FDG-PET-CT: An Imaging Biomarker of High-Risk Carotid Plaques. Correlation to Symptoms and Microembolic Signals
44. Glatiramer Acetate in the Treatment of Multiple Sclerosis: Emerging Concepts Regarding its Mechanism of Action
45. Multifocal motor neuropathy with high titers of anti-MAG antibodies
46. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
47. Long COVID Neuropsychological Deficits after Severe, Moderate, or Mild Infection.
48. Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
49. Cerebrospinal fluid features in SARS-CoV-2 RT-PCR positive patients
50. Serum neurofilament light chain captures and predicts confirmed progression independent of relapses (PIRA) in multiple sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.